Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Sigma-2 receptor is overexpressed in proliferating cancer cells, making it a target for imaging and potentially therapy.
• Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for DNA damage response.
• Investigating combined therapies for breast cancer is essential due to treatment resistance.

Purpose of the Study:

• To evaluate the synergistic cytotoxicity of combining PARP inhibitors with sigma-2 receptor ligands in breast cancer.
• To determine if this combination therapy can enhance cancer cell death and apoptosis.

Main Methods:

• Utilized breast cancer cell lines (EMT6 and MDA-MB-231).
• Administered PARP inhibitors (YUN3-6, olaparib) and sigma-2 receptor ligands (SV119, WC-26, RHM-138, SW43).
• Assessed cell viability, colony formation, apoptosis, and cell cycle progression.

Main Results:

• The PARP inhibitor YUN3-6 sensitized EMT6 cells to sigma-2 receptor ligands, increasing cell death.
• Olaparib sensitized MDA-MB-231 cells to SW43, inducing apoptosis and cell death.
• Olaparib inhibited PARP activity, proliferation, and caused G2/M cell cycle arrest in MDA-MB-231 cells.

Conclusions:

• The combination of sigma-2 receptor ligands and PARP inhibitors demonstrates synergistic potential for triggering cell death in specific breast cancer types.
• This combined therapeutic strategy warrants further investigation for its efficacy in cancer treatment.